sogat, berne 2006bts src berne ltd. evaluation of the procleix tigris system at the blood...
TRANSCRIPT
SoGAT, Berne 2006 BTS SRC Berne Ltd.
Evaluation of the Procleix Evaluation of the Procleix TIGRIS System at the Blood TIGRIS System at the Blood
Transfusion Service Berne Ltd.Transfusion Service Berne Ltd.
Dr. Martin Stolz
SoGAT, Berne 2006 BTS SRC Berne Ltd.
NAT testing in progressNAT testing in progress
HCV-PCR since 01 ‘1999 HIV-1 PCR since 03‘ 2002 increased blood safety automized test procedures
SoGAT, Berne 2006 BTS SRC Berne Ltd.
Procleix TIGRIS SystemProcleix TIGRIS System fully automated NAT screening system combined detection of 3 viruses: HIV-1, HCV and HBV extraction/amplification/detection in one tube extraction based upon magnetic
bead technology amplification based upon the
TMA technology using RNA as amplified targed
detection by chemiluminescence specific discrimination assays
for virus identification
SoGAT, Berne 2006 BTS SRC Berne Ltd.
Design of the evalution studyDesign of the evalution study
Assay validation: – sensitivity, specificity, robustness & cross-contamination
Test performance under routine conditions– routine samples– pools of 8 or individual donations– pooling with Tecan pipetting robots– analysis with Procleix TIGRIS system
SoGAT, Berne 2006 BTS SRC Berne Ltd.
SensitivitySensitivity
HIV-1: 24.9 IU/ml (95 % C.I.: 20.2 – 33.3 IU/ml)
ca. 13.9 copies/ml
HCV: 3.7 IU/ml (95 % C.I.: 3.1 – 4.8 IU/ml) ca. 23.3 copies/ml
HBV: 7.6 IU/ml (95 % C.I.: 6.0 – 11.1 IU/ml) ca. 41.0 copies/ml
SoGAT, Berne 2006 BTS SRC Berne Ltd.
Robustness and reproducibilityRobustness and reproducibility Procleix TIGRIS system: excellent robustness against
cross-contamination reproducibility: intra-, inter-assay precision and between
laboratories confirmed reliable test: 3 x 95% positive cut off value
(HIV-1: 75 IU/ml, HCV: 11 IU/ml, HBV: 23 IU/ml)
high robustness against inhibiting substances i.e. 100 I.U. heparin per sample
no interference with lipaemic or haemolytic samples as a frequent donation related factor
SoGAT, Berne 2006 BTS SRC Berne Ltd.
Specificity – System EvaluationSpecificity – System Evaluation
number of samples 1385 97.88% 1287 99.15% 2672 98.49%
number of invalids 14 0.99% 10 0.77% 24 0.88%
CLT: clot detected 2 0.14% 10 0.77% 12 0.44%
QNS: Insufficient sample for processing
6 0.42% 0 0.00% 6 0.22%
RDA: Reagent Dispense Failure - Amp
1 0.07% 0 0.00% 1 0.04%
initial reactive 16 1.13% 1 0.08% 17 0.63%
false reactive 15 1.06% 0 0.00% 15 0.55%
confirmed 1 0.07% 1*) 0.08% 2 0.07%
Pools of 8 combinedindividual donors
*) positive sample was a HBV window period donation
SoGAT, Berne 2006 BTS SRC Berne Ltd.
SummarySummary very good test sensitivity, robustness and reliability clear discrimination between reactive and non reactive samples low level of invalid samples elevated level of „false“ positives with pools of 8 observed pool resolving requires more time and large sample quantities fully automated NAT screening system test and software easy to handle high throughput: single donation testing feasable very high degree of automatisation, but demanding hardware
and little flexibility
SoGAT, Berne 2006 BTS SRC Berne Ltd.
AcknowledgmentsAcknowledgments
Christiane Schmidseder Rita Hubschmid Roger Hellmüller Dr. Christoph Niederhauser Dr. Philippe Schneider
(BTS Lausanne) Chiron Corp.
SoGAT, Berne 2006 BTS SRC Berne Ltd.
Window period HBV donationWindow period HBV donation
identified by single donation testing donation already transfused at time of testing recipient developed a HBV viraemie 3 weeks post
transfusion viral load of the initial donation not available, but… initial HBV titer must have been quite low:
no longer detectable in a dilution of 1:8 and 1:24
101'621 IU/ml in 2nd donation 35 days later